These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34389849)

  • 21. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
    Albershardt TC; Parsons AJ; Reeves RS; Flynn PA; Campbell DJ; Ter Meulen J; Berglund P
    Vaccine; 2020 Apr; 38(17):3369-3377. PubMed ID: 32088020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
    Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
    Front Immunol; 2021; 12():793831. PubMed ID: 34987517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
    Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
    Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
    Konala VM; Adapa S; Aronow WS
    Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients.
    Machiraju D; Wiecken M; Lang N; Hülsmeyer I; Roth J; Schank TE; Eurich R; Halama N; Enk A; Hassel JC
    Oncoimmunology; 2021 May; 10(1):1926762. PubMed ID: 34104542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired generalized lipodystrophy under immune checkpoint inhibition.
    Haddad N; Vidal-Trecan T; Baroudjian B; Zagdanski AM; Arangalage D; Battistella M; Gautier JF; Lebbe C; Delyon J;
    Br J Dermatol; 2020 Feb; 182(2):477-480. PubMed ID: 31077337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
    Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
    Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
    Front Immunol; 2021; 12():672521. PubMed ID: 34177913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
    Ahern E; Harjunpää H; O'Donnell JS; Allen S; Dougall WC; Teng MWL; Smyth MJ
    Oncoimmunology; 2018; 7(6):e1431088. PubMed ID: 29872559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.